Joura EA

ORCID: 0000-0003-0885-1013 · 1 paper in corpus

2022

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years.

Human vaccines & immunotherapeutics ·doi:10.1080/21645515.2022.2078626

Among women aged 27-45 years, the quadrivalent human papillomavirus (qHPV; HPV6/11/16/18) vaccine was generally well tolerated, efficacious, and immunogenic in the placebo-controlled FUTURE III study (NCT00090220; n = 3253). The qHPV vaccin…